Literature DB >> 34324661

Prognostic factor analysis for patient outcome of PD-L1 expression in thoracic oesophageal squamous cell carcinoma.

Bo Wu1, Jianhua Gao1, Muyuan Ma1, Yuanyuan Wu1, Xiaofeng Ye1.   

Abstract

OBJECTIVES: The purpose of this study was to determine the expression of PD-L1 in oesophageal squamous cell carcinoma (OSCC) and the prognostic factors.
METHODS: PD-L1 expression was investigated by immunohistochemical staining of resected specimens from 50 OSCC patients who were randomly selected from 104 patients with complete follow-up data. The relationships among PD-L1 expression, clinicopathological factors and prognosis were assessed by statistical analysis.
RESULTS: The expression of PD-L1 was positive in 27 (54%, positive cells' proportion > 25%) and negative in 23 (46%, positive cells proportion ≤25%) of 50 cases, and PD-L1 expression was negative in all pericarcinomatous tissues (P > 0.05). The 5-year survival rate of patients with PD-L1-positive expression was 22.2% (6 of 27), which was less than that of patients with PD-L1-negative expression (47.8%; 11 of 23) (P < 0.05). The results showed significant differences in the depth of tumour invasion, lymph node status, postoperative pathological stage and PD-L1 expression (P < 0.05). Multivariable analysis showed that PD-L1 expression was an independent prognostic factor for survival.
CONCLUSIONS: The depth of tumour invasion, lymph node status, postoperative pathological stage and PD-L1 expression are important factors affecting the prognosis of patients with thoracic OSCC; in particular, high PD-L1 expression was a significant independent poor prognostic factor in thoracic OSCC patients.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Oesophageal squamous cell carcinoma; PD-L1 expression; Prognosis

Mesh:

Substances:

Year:  2021        PMID: 34324661      PMCID: PMC8691681          DOI: 10.1093/icvts/ivab149

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  22 in total

1.  Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis.

Authors:  Hai-Xia Qu; Li-Ping Zhao; Shu-Hui Zhan; Chang-Xin Geng; Lin Xu; Yong-Ning Xin; Xiang-Jun Jiang
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

2.  Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.

Authors:  Yuichiro Ohigashi; Masayuki Sho; Yukishige Yamada; Yoshikazu Tsurui; Kaoru Hamada; Naoya Ikeda; Takashi Mizuno; Ryo Yoriki; Hisanori Kashizuka; Katsunari Yane; Fumihiko Tsushima; Noriko Otsuki; Hideo Yagita; Miyuki Azuma; Yoshiyuki Nakajima
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

3.  Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.

Authors:  Changsen Leng; Yin Li; Jianjun Qin; Jun Ma; Xianben Liu; Yingying Cui; Haibo Sun; Zongfei Wang; Xionghuai Hua; Yongkui Yu; Haomiao Li; Jun Zhang; Yan Zheng; Wei Wang; Junwei Zhu; Qiuming Wang
Journal:  Oncol Rep       Date:  2015-11-17       Impact factor: 3.906

4.  B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer.

Authors:  Lujun Chen; Haifeng Deng; Mingyang Lu; Bin Xu; Qi Wang; Jingting Jiang; Changping Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

5.  HOXC10 upregulation confers resistance to chemoradiotherapy in ESCC tumor cells and predicts poor prognosis.

Authors:  Daqin Suo; Zifeng Wang; Lei Li; Qingyun Chen; Tingting Zeng; Ranyi Liu; Jingping Yun; Xin-Yuan Guan; Yan Li
Journal:  Oncogene       Date:  2020-06-25       Impact factor: 9.867

Review 6.  The expression, function, and clinical relevance of B7 family members in cancer.

Authors:  Barbara Seliger; Dagmar Quandt
Journal:  Cancer Immunol Immunother       Date:  2012-06-14       Impact factor: 6.968

7.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

8.  Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.

Authors:  Koji Tanaka; Hiroshi Miyata; Keijiro Sugimura; Takashi Kanemura; Mika Hamada-Uematsu; Yu Mizote; Makoto Yamasaki; Hisashi Wada; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki; Hideaki Tahara
Journal:  Cancer Sci       Date:  2016-05-16       Impact factor: 6.716

9.  The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.

Authors:  Minghui Zhang; Yuandi Dong; Haitao Liu; Yan Wang; Shu Zhao; Qijia Xuan; Yan Wang; Qingyuan Zhang
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

10.  Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer.

Authors:  Ari J Rosenberg; Derek A Wainwright; Alfred Rademaker; Carlos Galvez; Matthew Genet; Lijie Zhai; Kristen L Lauing; Mary F Mulcahy; John P Hayes; David D Odell; Craig Horbinski; Srinadh Komanduri; Marie-Pier Tetreault; Kwang-Youn A Kim; Victoria M Villaflor
Journal:  Oncotarget       Date:  2018-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.